Network origin in Lars Ingvar Herbert Edvinsson first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Edvince AB
 Edvince AB BiotechnologyHealth Technology Edvince AB engages in clinical research and development services. It operates as a biotech company that focuses on a new form of emergency treatment for stroke. The company was founded by Lars Ingvar Herbert Edvinsson in 2003 and is headquartered in Lund, Sweden.
7
| Holding Company | Biotechnology | 7 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Lars Ingvar Herbert Edvinsson via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| IMMUNOVIA AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| SCANDION ONCOLOGY A/S | Pharmaceuticals: Major | Chairman Chairman | |
| University of Lund | College/University | Director/Board Member Doctorate Degree | |
| COEGIN PHARMA AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
| SPERMOSENS AB | Medical Specialties | Chief Executive Officer | |
| MONSENSO A/S | Internet Software/Services | Director/Board Member | |
InnovationsFonden
 InnovationsFonden Investment ManagersFinance InnovationsFonden provides investment services. It invests in entrepreneurs, researchers, and businesses. The company was founded on January 4, 2005 and is headquartered in Copenhagen, Denmark. | Investment Managers | Chief Executive Officer | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
VINNOVA AB
 VINNOVA AB Financial ConglomeratesFinance VINNOVA AB provides funding services and financial assistance. It promotes collaborations between companies, universities, research institutes and the public sector. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Financial Conglomerates | Corporate Officer/Principal | |
S:t Eriks Ögonsjukhus AB
 S:t Eriks Ögonsjukhus AB Hospital/Nursing ManagementHealth Services S:t Eriks Ögonsjukhus AB operates eye hospitals. It specializes in corneal transplant; medical and surgical treatments of retina; oculoplastic surgery, ophthalmic oncology and pathology services; and medical contact lens service for infants and children. The company is headquartered in Stockholm, Sweden. | Hospital/Nursing Management | Director/Board Member | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Coegin Pharma AS
 Coegin Pharma AS Pharmaceuticals: MajorHealth Technology Coegin Pharma AS provides therapeutics that addresses inflammatory diseases. The company was founded by Berit Johansen on January 3, 2005 and is headquartered in Trondheim, Norway. | Pharmaceuticals: Major | Chief Executive Officer | |
| University of Bergen | College/University | Undergraduate Degree | |
| University of Strasbourg | College/University | Doctorate Degree | |
| GENOVIS AB | Medical Specialties | Chief Executive Officer | |
| Louis Pasteur University | College/University | Doctorate Degree | |
Glycom A/S
 Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Biotechnology | Founder | |
Copenhagen Institute for Futures Studies
 Copenhagen Institute for Futures Studies Miscellaneous Commercial ServicesCommercial Services Copenhagen Institute for Futures Studies is an institution that specializes in providing futures studies. The non-profit company is based in Copenhagen, Denmark. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Sapiens Denmark A/S
 Sapiens Denmark A/S Packaged SoftwareTechnology Services Tia Technology A/S develops software applications for insurance industry. It also offers administration, claims, handling, life and pension, as well as country functionality services. The company was founded by Peter Schrøder, Hans Agerlin Petersen, and Lars Lorentzen on May 1, 1997 and is headquartered in Virum, Denmark. | Packaged Software | Director of Finance/CFO | |
Mckinsey & Co. Denmark P/S
 Mckinsey & Co. Denmark P/S Miscellaneous Commercial ServicesCommercial Services Part of McKinsey & Co., Inc., Mckinsey & Co. Denmark P/S is a Danish company that provides business and other management consultancy services. The company is based in Copenhagen, Denmark. | Miscellaneous Commercial Services | Chairman | |
Rehaler ApS
 Rehaler ApS Medical SpecialtiesHealth Technology Rehaler ApS develops medical devices for the treatment of migraine. | Medical Specialties | Director/Board Member | |
| XINTELA AB | Biotechnology | Chief Tech/Sci/R&D Officer | |
| CYXONE AB | Pharmaceuticals: Major | Chief Executive Officer | |
| Lund University School of Economics & Management | College/University | Masters Business Admin | |
CanImGuide Therapeutics AB
 CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
| Immodulate Pharma AB | Chief Executive Officer | ||
| Technical University of Denmark | College/University | Graduate Degree | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Founder | |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Sparbanksstiftelsen Skånes Riskkapitalstiftelse
 Sparbanksstiftelsen Skånes Riskkapitalstiftelse Financial ConglomeratesFinance Sparbanksstiftelsen Skånes Riskkapitalstiftelse invests in high-risk projects. The firm seeks to invest in the form of share acquisitions, possibly combined with shareholder's contributions or convertible loans and the investment can be initial, as well as a follow-on investment. The company was founded in 2007 and is headquartered in Malmo, Sweden. | Financial Conglomerates | Director/Board Member | |
| GeccoDots AB | Director/Board Member | ||
Swednano Tech AB
 Swednano Tech AB Financial ConglomeratesFinance Swednano Tech AB provides financial support services. The private company is based in Stockholm, Sweden. | Financial Conglomerates | Director/Board Member | |
| ACUCORT AB | Pharmaceuticals: Major | Director/Board Member | |
Respiratorius AB
 Respiratorius AB Pharmaceuticals: MajorHealth Technology Respiratorius AB engages in the development of drug candidates for Chronic Obstructive Pulmonary Disease, asthma, and cancer. The company was founded by Lars Christer Fedrik Fåhraeus and Staffan Skogwall in 1999 and is headquartered in Lund, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
SwedenBIO Service AB
 SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
Aqilion AB
 Aqilion AB Investment ManagersFinance Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden. | Investment Managers | Chief Executive Officer | |
| Nanoecho AB | Director/Board Member | ||
| BumbleFish AB | Director/Board Member | ||
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Scandinavian Society for Psychopharmacology | Corporate Officer/Principal | ||
| Collegium Internationale Neuro-Psychopharmacologicum | Corporate Officer/Principal | ||
| Eijdo Research AB | Director/Board Member | ||
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Founder | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistics
International
| Sweden | 23 |
| Denmark | 18 |
| Norway | 3 |
| France | 3 |
| Netherlands | 2 |
Sectoral
| Health Technology | 20 |
| Consumer Services | 8 |
| Finance | 8 |
| Commercial Services | 5 |
| Technology Services | 3 |
Operational
| Director/Board Member | 31 |
| Chief Executive Officer | 13 |
| Chairman | 11 |
| Founder | 9 |
| Corporate Officer/Principal | 9 |
Most connected contacts
| Insiders | |
|---|---|
| Peter Andersen | 26 |
| Inga Sarah Maria Fredriksson | 13 |
| Tore Duvold | 11 |
| Martin Møller | 8 |
| Carl Magnus Högerkorp | 7 |
| Jesper Kihl | 4 |
| Johanna Adami | 3 |
- Stock Market
- Insiders
- Lars Ingvar Herbert Edvinsson
- Company connections
